AUG 11 2000

Express Mail No.: EK611852561US

Date of Delivery: August 3, 2000

Attorne

Attorney Docket No. 00960-515 (CRP-145)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

LICANTS

Cohen et al.

ASSIGNEE:

Creative BioMolecules, Inc.

SERIAL NUMBER:

08/851,628

EXAMINER:

D. Romeo

FILING DATE:

May 6, 1997

ART UNIT:

1646

For:

NOVEL THERAPIES FOR CHRONIC RENAL FAILURE

Assistant Commissioner for Patents Washington, D.C. 20231

REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

CREATIVE BIOMOLECULES, INC., a company and owner of the above-identified United States patent application U.S.S.N. 08/851,628, filed May 6, 1997, assignment recorded on November 28, 1997, at Reel 8827/Frame 0589, hereby revokes any and all former powers of attorney and appoints:

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
David B. Bernstein	32,112	Barry J. Marenberg	40,715
David F. Crosby	36,400	William A.Marino	44,219
James G. Cullem	43,569	Leslie Meyer-Leon	37,381
Brett N. Dorny	35,860	A. Jason Mirabito	28,161
Marianne Downing	42,870	Michel Morency	Limited Recognition
Ivor R. Elrifi	39,529	Carol H. Peters	45,020
Heidi A. Erlacher	45,409	John T. Prince	43,091
John A. Harre	37,345	Mike Renaud	44,299
Shane Hunter	41,858	Brian Rosenbloom	41,276
David E. Johnson	41,874	Thomas M. Sullivan	39,392
Christina Karnakis	45,899	Howard Susser	33,556
Robert Klauzinski	42,742	Shelby Walker	45,192
Kristin E. Konzak	44,848	Martin M. Zoltick	34,745
Cynthia Kozakiewicz	42,764		•

APPLICATION No.

08/851,628 Cohen *et al.*

APPRICANTS:

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

Ivor R. Elrifi Mintz Levin

Ivor R. Elrifi, or

One Financial Center

Michel Morency (617) 542-6000

Boston, MA 02111

CREATIVE BIOMOLECULES, INC. certifies under 37 C.F.R. § 3.73(b) that it is the Assignee of the entire right, title and interest in the patent identified above by virtue of assignments of the above identified patent.

I, the undersigned, am empowered to act on behalf of the Assignee. Acting on behalf of the Assignee, I have reviewed all the documents in the chain of title of the patent identified above and, to the best of my knowledge and belief, title is in the Assignee identified above.

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the patent.

Please charge any fee or any fee deficiency occasioned by this document to Deposit Account No. 50-0311 Reference No. 00960-515).

Respectfully submitted,

Cheryl Lawton

Vice President, General Counsel

CREATIVE BIOMOLECULES, INC.

Date: $\frac{\cancel{f}, \cancel{U}}{\cancel{U}}$, 2000

TRADOCS:1235307.1(QH6301!.DOC)

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE

LIMITED RECOGNITION UNDER 37 CFR §10.9(b)

Michel Morency is hereby given limited recognition under 37 CFR §10.9(b), as an employee of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., to prepare and prosecute patent applications and to represent patent applicants wherein the patent applicants are clients of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., and wherein a registered practitioner who is a member of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. is the attorney or agent of record. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Michel Morency ceases to lawfully reside in the United States; (ii) Michel Morency's employment with the Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., law firm ceases or is terminated; or (iii) Michel Morency ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: January 4, 2001

Harry I. Moatz, Acting Director
Office of Enrollment and Discipline

Express Mailing Label No. EK611852561US Attorney Reference No. 00960-515